[Form 4] Kiniksa Pharmaceuticals International, plc Insider Trading Activity

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals (KNSA) reported an insider transaction by its Chief Financial Officer. On 10/28/2025, the CFO exercised 100 share options at $30.93 and sold 100 Class A Ordinary Shares at $41.00, executed under a Rule 10b5-1 plan dated September 3, 2024. Following these trades, the officer directly owned 31,086 shares and held 19,900 options with an expiration of 09/19/2028. The option was fully vested and exercisable.

Insights

Insider transactions analyst

Routine 10b5-1 option exercise and matching sale; neutral impact.

The CFO exercised 100 options at $30.93 and sold 100 shares at $41.00 on 10/28/2025, pursuant to a pre-established Rule 10b5-1 plan. Such plans automate trades to reduce discretion and potential timing concerns.

Post-transaction holdings are 31,086 shares directly and 19,900 options expiring on 09/19/2028. The filing describes the option as fully vested and exercisable. Actual market impact depends on broader trading volumes and holder decisions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ragosa Mark

(Last) (First) (Middle)

23 OLD BOND STREET, THIRD FLOOR

(Street)

LONDON X0 W1S 4PZ

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
10/28/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	10/28/2025		M(1)		100	A	$30.93	31,186	D
Class A Ordinary Share	10/28/2025		S(1)		100	D	$41	31,086	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option	$30.93	10/28/2025		M(1)			100	(2)	09/19/2028	Class A Ordinary Share	100	$0	19,900	D

Explanation of Responses:

1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024.

2. The option is fully vested and exercisable.

	/s/ Douglas Barry, Attorney-in-Fact	10/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did KNSA’s CFO report on Form 4?

The CFO exercised 100 options at $30.93 and sold 100 shares at $41.00 on 10/28/2025.

Was the KNSA trade under a Rule 10b5-1 plan?

Yes. The transaction was effected under a Rule 10b5-1 plan executed on September 3, 2024.

How many KNSA shares does the officer own after the trade?

Direct ownership is 31,086 Class A Ordinary Shares following the reported transactions.

How many options remain after the transaction?

The officer reported 19,900 derivative securities (options) remaining after the transaction.

What was the option exercise and sale price?

The option was exercised at $30.93 per share; the sale price was $41.00 per share.

When do the remaining options expire?

The options have an expiration date of 09/19/2028.

Were the options vested?

Yes. The filing notes the option is fully vested and exercisable.